BLUE Share Price Performance
US$4.97
-15.23 (-75.40%)
37.9% undervalued intrinsic discount
US$8.00
Fair Value
Price US$4.97
AnalystConsensusTarget US$8.00
Fair ValueUS$8.00
Share PriceUS$4.97
37.9% undervalued intrinsic discount
BLUE Community Narratives
AN
Fair Value US$8.00 23.5% undervalued intrinsic discount
Patient Starts And Capacity Expansion Will Achieve Breakeven
0users have liked this narrative
0users have commented on this narrative
12users have followed this narrative
Recent BLUE News & Updates
No updates
bluebird bio, Inc. Key Details
Last Reported Earnings
Mar 31, 2025
Next Reporting Earnings
n/a
- Earnings per share (EPS)
- -20.42
- Gross Margin
- 27.12%
- Net Profit Margin
- -192.39%
- Debt/Equity Ratio
- -175.5%
bluebird bio, Inc. Competitors
About BLUE
- Founded
- 1992
- Employees
- 248
- CEO
- WebsiteView website
bluebird bio, Inc., a biotechnology company, researches, develops, and commercializes gene therapies for curative severe genetic diseases in the United States. The company’s product candidates for severe genetic diseases include ZYNTEGLO (betibeglogene autotemcel) for the treatment of transfusion-dependent ß-thalassemia; LYFGENIA (lovotibeglogene autotemcel) for the treatment of sickle cell disease (SCD) and a history of vaso-occlusive events; and SKYSONA (elivaldogene autotemcel) to treat cerebral adrenoleukodystrophy. Its clinical development programs include HGB-205, HGB-206, and HGB-210 to evaluate the safety and efficacy of lovo-cel in the treatment of patients with SCD; and HGB-204, HGB-205, HGB-207, and HGB-212 to evaluate the safety and efficacy of beti-cel in the treatment of patients with ß-thalassemia. The company was formerly known as Genetix Pharmaceuticals, Inc., and changed its name to bluebird bio, Inc. in September 2010. bluebird bio, Inc. was incorporated in 1992 and is headquartered in Somerville, Massachusetts.
U.S. Market Performance
- 7 Days: 0.2%
- 3 Months: 12.2%
- 1 Year: 19.9%
- Year to Date: 7.6%
The Consumer Staples sector gained 3.2% while the market remained flat over the last week. More promisingly, the market is up 20% over the past year. As for the next few years, earnings are expected to grow by 15% per annum. Market details ›
This week, we are weighing up the potential productivity gains vs job losses and economic disruption that the global economy could face over the next decade and beyond.
Continue reading